GlassScriptPhysician profile
Samish Dhungana
NPI 1316275035
$8,896.36
in general payments reported to CMS, 2019-2025
60 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $617 · 2021: $1,084 · 2022: $1,024 · 2023: $1,381 · 2024: $1,368 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,167 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,167.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.65 | 2020-2025 | Botox, Qulipta, Ubrelvy |
| Emd Serono, INC. | $583.87 | 2019-2025 | Mavenclad |
| Ucb, INC. | $473.34 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Celgene Corporation | $363.81 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $327.21 | 2019-2025 | Ultomiris |
| Allergan, INC. | $326.32 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $321.69 | 2019-2025 | Nuplazid |
| Amgen INC. | $319.42 | 2019-2025 | Aimovig |
| Eisai INC. | $282.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $243.13 | 2019-2025 | |
| Pfizer INC. | $212.93 | 2022-2025 | |
| Biogen, INC. | $203.64 | 2019-2025 | Tysabri, Vumerity |
| Neurelis, INC. | $199.85 | 2021-2025 | Valtoco |
| Genzyme Corporation | $191.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $189.52 | 2019-2020 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samish Dhungana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.